A series of subclones ofJ774.2 were picked and screened for their ability to bind IgGs. J774.2.1 was found to lack IgGs receptors. It has grown to mass culture and recloned to produce J774.2.1.4. P388D1 is a macrophagelike cell line with Fc receptors and phagocytic ability. FCI.4 and FC1.6 are subclones of the FC1 cell line which arose during a fusion of MPC 11 myeloma ceils to spleen cells from a BALB/e mouse immunized with SRBC. FC 1. 4 and FC 1.6 were selected for their inability to phagocytize IgG~-SRBC.
Primary macrophages were obtained from resident peritoneal cells and from peritoneal cells 4 d after an intraperitoneal injection of thioglycolate broth (Difco Laboratories, Detroit, Mich.). The method for isolating adherent cells has been described previously (1).
Myeloma Proteins. Myeloma proteins were obtained by injecting 107 MOPC21 (IgGa), MPCll (IgG~b), MOPC173 (IgG2a), or J606 (IgGa) cells into the peritoneal cavity of pristineprimed BALB/c mice (16) . The aseites fluid was precipitated with 50% saturated ammonium sulfate. A purified -/-globulin fraction was obtained by DEAE chromatography (1). It was determined by agarose gel electrophoresis and by Ouchterlony analysis that no fraction had any contaminating protein of another subclass. Flope 21 was purchased from Bionetics, Kensington, Md. Monomeric protein was prepared by centrifuging the protein for 30 min at 150,000 g.
Preparation ofIg-coated SRBC. The methods of Bianco et al. (17) were used. SRBC were incubated with antibody for 30 min at 37°C, washed, and resuspended to 0.5%. The antibodies were obtained from cloned hybridoma lines making anti-SRBC antibody, 5 #1 of ascites fluid was incubated with 1 ml of a 5% solution of SRBC.
The IgGs-producing line was derived from a fusion of drug-marked P3 cells with spleen cells from a BALB/c mouse immunized with SRBC. Segregants no longer making the myeloma IgG1 heavy chain were selected. The IgGz antibody was identified by Ouchterlony analysis with commercial anti-IgG3 (Meioy Laboratories, Inc., Springfield, Va.) and with antiserum raised in the laboratory of Dr. John Cebra, University of Pennsylvania, against J606 protein and absorbed with IgGa, Ig~a, and IgG2b.
Fc Rosettes and Fc-mediated Phagocytosis. This was done as previously described (1). Cells adhered to glass coverslips were incubated for 30 min at 37 ° or 4°C, washed, and assayed for rosettes. Attachment of three or more SRBC signified a rosette. For phagoeytosis, the cells were incubated for 1 h at 37°C, free SRBC were lysed in hypotonic solution, and intracellular SRBC were assayed. A phagocytic cell was any cell with three or more ingested SRBC. Controls were run with SRBC incubated in normal mouse serum, and <5% of cells rosetted or phagocytized. To study the effect of trypsin and cytochalasin, macrophages were incubated in 1 mg/ml of crystallized trypsin in phosphate-buffered saline (PBS), or 10 pg/ml of eytochalasin B (Aldrich Chemical Co., Inc., Milwaukee, Wis.) in PBS for 30 rain at 37°C, washed, and assayed for rosetting ability.
Inhibition of Binding by Myeloma Proteins
J606 (IgGs), or Flopc 21 (IgGs) protein was aggregated with bis-diazotized benzidine (BDB) (18) . Macrophages were pretreated for 5 rain with the myeloma protein in PBS and then Ig-SRBC were added. Rosettes were assayed at 20 rain. The titer of the anti-SRBC antibody in each case was 1:500 using indirect hemagglutination with an anti-x antibody. The SRBC were washed and assayed for rosette formation.
Inhibitwn of Binding by Protein

Results
IgGa-coated SRBC formed rosettes with primary resident and thioglycolate-induced peritoneal macrophages, and with J774.2 and P388DI cell lines (Table I) .
In competitive inhibition experiments (Tables I and II) , aggregates of IgG1, IgG2a, and IgG2b all failed to inhibit rosetting of IgGs-coated SRBC, suggesting a separate receptor for IgGa. In contrast, two IgGa myeloma proteins, Flopc 21 and J606, did inhibit rosetting when aggregated chemically with BDB. These results imply that the IgG3 antibody is binding to the macrophage through its Fc terminal. Monomeric IgG3 did not inhibit rosetting. The rosetting of IgG3-SRBC was unaffected at 4°C, by cytochalasin B, or by trypsinization of the macrophages. In this respect, the IgGa receptor behaves like the receptor for IgG1 and IgG2b and unlike the receptor for IgG2a, which is altered at 4°C, and by both cytochalasin and trypsin.
Although inhibition of rosetting by aggregated IgGa suggested that the binding of antibody-coated SRBC was Fc mediated, we wanted to show by a second method that IgGa was bound to receptors on macrophages through its Fc portion. We therefore examined whether protein A could inhibit the binding of IgGa. Protein A will bind to the Fc portion of several immunoglobulins, including IgG3 and IgG2. It binds poorly to IgG1 (19) . It has been further shown that protein A will compete with Fc receptors for Fc binding (20) . When protein A was incubated with IgG3-coated SRBC, it inhibited rosette formation. As expected, it also inhibited rosetting of IgG2-coated SRBC and not of IgGrcoated SRBC (Table III) .
J774.2.1.4 is a randomly picked subclone ofJ774.2. It did not rosette IgGa-SRBC (Tables II and IV) . These data again suggest that the receptor for IgG3 is independent of the other IgG receptors.
We have previously reported variants from the FC 1 macrophage cell line that have altered phagocytosis through the IgG~ receptor (1). These variant lines with a selective defect in phagocytosis were both able to phagocytize IgGa-coated SRBC, suggesting again that the IgGa receptor is independent of the IgG2a receptor (Table   V) .
Discussion
It has previously been thought that IgG3 does not bind to Fc receptors on mouse macrophages. This was based on data showing the inability of IgG3 to compete successfully with IgG2a for Fc binding (14) . It has since become clear that macrophages possess more than one Fc receptor and that each receptor has a restricted specificity (1, 5, 12). Two receptors have been clearly defined: one for IgG1 and IgG2b, and the other for IgG2a (4, 13) .
The studies reported here indicate that there is also a separate Fc receptor on mouse macrophages for IgG3. This Fc receptor is present on resident peritoneal macrophages as well as on thioglycolate-induced macrophages. In addition, the J774.2 cell line and the P388Dl cell line exhibit this receptor. This receptor is independent from the two previously identified receptors because (a) the other IgG subclasses do not compete with IgGs for binding; (b) J774.2.1.4, a subclone of J774.2, is unable to bind or phagocytize IgGa complexes but is unaffected in its IgG2~ and IgGa-IgG2b receptors; and, (c) variants of the FC1 line that are altered in their ability to phagocytize through the IgG2a receptor have an intact ability to phagocytize IgGa-SRBC.
The IgGs Fc receptor is similar to the receptor for IgGa and IgG2b in that it is not affected at 4°C or by cytochalasin B or trypsin. It resembles the other IgG receptors in its ability to mediate phagocytosis. In addition, we have reported that IgG3 can also mediate antibody-dependent cell-mediated cytolysis of SRBC.
Fc RECEPTOR ON MOUSE MACROPHAGES BINDING IgGs
That IgGs should bind through a separate receptor is not surprising, because structurally and serologically it is the most dissimilar of the I.gG subclasses (14) . The identification of this third receptor, however, raises again the question of why several independent Fc receptors are present on macrophages. On macrophages, each receptor is capable of mediating both phagocytosis and antibody-dependent cell-mediated cytolysis (21) . Other cell types that bear Fc receptors may possess only one or two of these receptors in order to restrict their response to antibody or immune complexes (8, 22, 23) . If Fc receptors on other cell types have the same specificity as on macrophages, perhaps the multiplicity of receptors allows for antibody-specific responsiveness in other cell types. The multiplicity may be a consequence of the amount of information that must be carried in the constant region of the immunoglobulin molecule; the constraints of subclass specificity may make separate Fc receptors necessary. Further studies on both the biologically active sites of the IgG molecules and the nature of Fc receptors on other cell types are necessary to resolve these questions.
Summary
Monoclonal antibodies to sheep erythrocytes (SRBC) have proved useful in identifying two Fc receptors on mouse macrophages, one for IgG2a, and one for IgG1 and IgG2b. We have used monoclonal IgG3 anti-SRBC to identify a third Fc receptor on mouse macrophages which binds IgG3 uniquely. This receptor is present on primary resident and thioglycolate-induced peritoneal macrophages and on some macrophage cell lines. The binding of IgGa-coated SRBC is inhibited by aggregated but not monomeric IgGa, and not by IgG1, IgG2., and IgGeb aggregates. It is unaffected by treating the macrophages with trypsin or cytochalasin B and occurs at both 4 ° and 37°C. IgGs, like all other IgG subclasses, mediates phagocytosis. We have also generated a variant macrophage line which bears the receptors for IgGa and IgG2b and for IgG2,, but not for IgGs.
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